Camicinal hydrochloride is primarily investigated for its potential therapeutic applications in gastrointestinal disorders, particularly those related to impaired gastric motility. It acts as a motilin receptor agonist, which stimulates muscle contractions in the stomach and intestines, aiding in the acceleration of gastric emptying. This mechanism makes it a promising candidate for treating conditions like gastroparesis, a disorder where the stomach empties too slowly, often seen in patients with diabetes or post-surgical complications. Additionally, it has been explored for its potential to alleviate symptoms of functional dyspepsia and other motility-related gastrointestinal issues. Clinical studies have focused on its efficacy and safety profile, aiming to provide relief for patients suffering from chronic digestive discomfort and delayed gastric emptying.